Ebanga®
Company
Ridgeback Biotherapeutics
Use
Treatment of Zaire ebolavirus infection.
Features
Human monoclonal antibody, blocks virus binding to cell receptors.
NIH Contribution
Research and antibody development resulting in a promising Ebola treatment via mAb114.
HHS Institute/Agency
NIAID
Inventor(s)
Sullivan, N. et al.
Year
2022
